Literature DB >> 12756089

Long-term results after external beam radiation therapy for T1-T2 localized prostate cancer.

B W Lagerveld1, M P Laguna, J J M C H de la Rosette.   

Abstract

The incidence of organ-confined and early-stage prostate cancer has increased. The external beam radiation therapy has proven to be a good therapeutic option in terms of biochemical survival and overall survival. It has been modified throughout the years; consequently, the available data on the long-term efficacy of external beam radiation therapy are difficult to compare with the commonly used improved radiation strategies. Intensity-modulated conformal radiotherapy and three-dimensional conformal radiotherapy result in better tumor control at a lower complication rate. External beam radiotherapy seems to be favored in intermediate- and high-risk groups for relapse of prostate cancer and radical prostatectomy is favored in the low-risk group. However, they score similarly in terms of general health-related quality of life after treatment.

Entities:  

Mesh:

Year:  2003        PMID: 12756089     DOI: 10.1007/s11934-003-0076-1

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  43 in total

1.  Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.

Authors:  C A Lawton; K Winter; K Murray; M Machtay; J B Mesic; G E Hanks; C T Coughlin; M V Pilepich
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-15       Impact factor: 7.038

Review 2.  Long-term control of prostate cancer with radiation. Past, present, and future.

Authors:  G E Hanks
Journal:  Urol Clin North Am       Date:  1996-11       Impact factor: 2.241

3.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

Authors:  A W Partin; M W Kattan; E N Subong; P C Walsh; K J Wojno; J E Oesterling; P T Scardino; J D Pearson
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

4.  Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy.

Authors:  P R Anderson; A L Hanlon; E Horwitz; W Pinover; G E Hanks
Journal:  Cancer       Date:  2000-12-15       Impact factor: 6.860

5.  Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.

Authors:  S H Stokes
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-04-01       Impact factor: 7.038

6.  Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer.

Authors:  F J Fowler; M McNaughton Collins; P C Albertsen; A Zietman; D B Elliott; M J Barry
Journal:  JAMA       Date:  2000-06-28       Impact factor: 56.272

7.  Three-dimensional intrafractional movement of prostate measured during real-time tumor-tracking radiotherapy in supine and prone treatment positions.

Authors:  Kei Kitamura; Hiroki Shirato; Yvette Seppenwoolde; Rikiya Onimaru; Makoto Oda; Katsuhisa Fujita; Shinichi Shimizu; Nobuo Shinohara; Toru Harabayashi; Kazuo Miyasaka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-08-01       Impact factor: 7.038

8.  Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer.

Authors:  Joost J Nuyttens; Steve Milito; Philip F Rust; Andrew T Turrisi
Journal:  Radiother Oncol       Date:  2002-08       Impact factor: 6.280

9.  Long-term outcome of radical radiation therapy for prostatic carcinoma: 1967-1987.

Authors:  P Hahn; E Baral; M Cheang; M C Math; J Kostyra; R Roelss
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-01-01       Impact factor: 7.038

10.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.

Authors:  P C Albertsen; J A Hanley; D F Gleason; M J Barry
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.